Phenoxodiol has been developed as a therapy for
- early-stage prostate cancer
- late-stage, hormone-refractory prostate cancer
- early stage cervical and vaginal cancer
- chemo-resistant and chemo-refractory ovarian cancer.
Phenoxodiol is a broad-spectrum anti-cancer drug that induces cancer cell death through inhibition of anti-apoptotic proteins including XIAP and FLIPshort.
The mechanism of action of phenoxodiol suggests its potential to be used both as a monotherapy and in combination with standard anti-cancer drugs where it acts to enhance the efficacy of those drugs in chemo-sensitive patients and to restore sensitivity to those drugs in chemo-resistant patients.
Phenoxodiol currently is undergoing clinical studies in the USA, Europe and Australia.
|
